H1-histamine receptors in the amygdala are involved in emotional memory but do not mediate anxiety-related behaviors in mice submitted to EPM testing  by Serafim, K.R. et al.
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a  b  s  t  r  a  c  t
This  study  investigated  the  role  of  amygdala  H1 receptors  in state-dependent  memory  deﬁcits  induced  by
l-histidine  (LH).  Tests  using  an  elevated  plus-maze  (EPM)  were  performed  on  two  consecutive  days:  Trial
1  (T1)  and  Trial  2  (T2).  Before  each  trial,  mice  were  intraperitoneally  (IP)  injected  with  LH  (500  mg/kg).
Two  hours  later,  they  were  microinjected  with  the  H1 receptor  antagonist,  chlorpheniramine  (CPA  0.016,
0.052,  or  0.16  nmol/0.1  l), or saline  (SAL)  into  the  amygdala  and  submitted  to  the  EPM.  LH-CPA  did  not
affect  trial  1  performances  in  the EPM,  which  indicated  that  these  drugs  did not  affect  anxiety. Emotional
memory,  as  revealed  by  a reduction  in  open  arm  exploration  between  both  trials,  was  present  in the
SAL–SAL  groups  as well  as in  the  SAL–CPA  groups  for the  lower  doses  of  CPA (0.016  and  0.052  nmol).
On  the contrary,  neither  the  LH–SAL  group  nor  the LH–CPA  groups  exhibited  this  decrease  in  open  arm
activity  between  both  trials,  which  reveals  that  LH impaired  emotional  memory.  While intra-amygdalarlevated plus-maze
ice
CPA  did  not  interact  with  LH  effect,  it impaired  per se the  emotional  memory  performances  at  the  highest
dose  (0.16  nmol).  No signiﬁcant  changes  were  observed  in  the  number  of enclosed  arm  entries  (EAE),  an
EPM index  of  general  exploratory  activity.  These  results  may  be  attributed  to  a combined  effect  in the
different  nucleus  of  the  amygdala.  Taken  together,  these  results  suggest  that  the  H1 receptors  in the
amygdala  are  not  implicated  in  anxiety-like  behaviors  but  are  involved  in emotional  states  induced  by
the T1/T2  EPM  protocol  in  mice.. Introduction
Neuronal histamine has been implicated in cognition functions,
ncluding learning and memory (Brown et al., 2001; Haas et al.,
008). Histamine functions are mediated through different recep-
ors subtypes: H1, H2, H3 and H4 (Leurs et al., 1995; Strakhova
t al., 2009). Additionally, high density of postsynaptically located
istamine H1 has been found in limbic regions, including the amyg-
ala (Ryu et al., 1995). The amygdala has been known to play an
Abbreviations: LH, l-histidine; EPM, elevated plus-maze; T1, Trial 1; T2, Trial 2;
ntraperitoneally, IP; CPA, chlorpheniramine; SAL, Saline; %OAE, percentage of open
rm entries; %OAT, percentage of open arm time; ANOVA, analysis of variance; OAE,
pen arm entries; EAE, enclosed arm entries; OAT, open arm time; EAT, enclosed
rm time; CT, central area time; mPFC, Medial portion of the prefrontal cortex; 5-HT,
erotonin; I.C.V, intracerebroventricular; IA, Intra-amygdala; NBM, nucleus basalis
agnocellularis.
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important regulatory role in the acquisition of emotionally based
learning and memory (Alvarez and Ruarte, 2002; Ribeiro et al.,
2011); further, it is demonstrated a lateralized participation of the
amygdala on exploratory behavior and histamine neurons appear
mediate these differential modulations (Alvarez and Banzan, 2011).
Anatomic data have shown that the amygdala receives afferences
from the tuberomamillary nucleus (TM) of the posterior hypotha-
lamus, the major source of brain histamine (Haas et al., 2008).
Evidence has demonstrated that histamine can facilitate long-term
potentiation (LTP) by activating histamine receptor subtypes (Haas
et al., 2008; Luo and Leung, 2010). A study conducted by Jiang
(2005) showed that in vitro, histamine can increase excitatory
synaptic transmission in the amygdala; Furthermore, it is accepted
that synaptic plasticity within the amygdala is the cellular basis of
emotional memory because LTP is correlated with memory trace
formation (Haas et al., 2008).
The widespread extension of histaminergic neurons modulat-
ing neuronal activity in other brain structures, such as the locus
Open access under the Elsevier OA license.coeruleus that presents a pathway for neuromodulator interaction
with the amygdala (Alvarez, 2009; Haas et al., 2008; McGaugh,
2004); it has been suggested that the histaminergic system may
exert tonic modulatory control over emotional behavior (Santos
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t al., 2001). In addition, some evidence supports the concept
hat histaminergic neurons inﬂuence learning and memory via
1 histaminergic receptor activation (Alvarez and Banzan, 2008;
asuoka et al., 2010). Indeed, intra-hippocampal administration
f histamine in rats has been shown to interfere with the consol-
dation of the avoiding response, affecting latency and memory
fﬁciency, and this interference was mediated by histamine H1
eceptors (Alvarez and Banzan, 2008). In mice, intracerebroventric-
lar administration of histamine H1 receptor antagonist prevented
he improving effect of pre-test lithium on memory retrieval
Zarrindast et al., 2008). In humans, oral administration of diphen-
ydramine, an H1-receptor antagonist, induced attentional and
orking-memory impairments (Kay and Harris, 1999). Although
he studies have indicated that histamine H1 receptors could have
 modulatory action on memory processes, few studies have inves-
igated histamine effects mediated by H1 receptors present in the
mygdala on emotional memory using repeated testing in an ele-
ated plus-maze test.
A model used to detect the inﬂuence of emotional states on
emory in a repeated measures protocol is the elevated plus-
aze (EPM) (Carobrez and Bertoglio, 2005). The EPM is a widely
sed test of animal anxiety (Lister, 1987; Pellow et al., 1985), and
ccording to Galvis-Alonso et al. (2010),  animals acquire informa-
ion about safe and dangerous areas of the maze during EPM testing.
epeated testing provides a measure of acquisition and memory
etention because experience-dependent behavioral changes can
e observed. Recently, we  demonstrated that intraperitoneal (IP)
njection of l-histidine (LH), a precursor of histamine, induces a
tate-dependent memory retrieval deﬁcit in mice when repeatedly
xposed to the EPM (Gianlorenc¸ o et al., 2011; Seraﬁm et al., 2010).
owever, our research group did not account for the involvement
f H1 receptor modulation in the amygdala on emotional behaviors.
Therefore, the aim of this study was to verify whether the effects
f LH on emotional memory retrieval in mice are mediated by H1
eceptors in the amygdala. To address this question, we investi-
ated the effects of microinjection H1 antagonist chlorpheniramine
CPA) into the amygdala on anxiety and emotional memory in mice
reviously treated with LH and re-exposed to the EPM.
. Material and methods
.1. Animals
The experimental subjects were 117 adult male Swiss mice
Federal University of São Carlos, SP, Brazil) weighing 25–32 g
t testing. The mice were housed in groups of 4 per cage
28 cm × 18 cm × 11 cm)  and maintained under a 12-h light cycle
lights on at 7 A.M.) in a controlled environment at a temperature
f 23 ± 1 ◦C and with a relative humidity of 50 ± 5%. Food and drink-
ng water were provided ad libitum, except during the brief testing
eriods. All mice were experimentally naïve at the beginning of the
tudy. The experimental sessions were conducted during the light
eriod of the cycle (9 A.M.–4 P.M.).
.2. Drugs
l-histidine hydrochloride (a precursor of histamine) (Sigma,
O,  USA) and chlorpheniramine maleate salt (an H1 receptor
ntagonist; Sigma Chemical Co., St. Louis, MO)  were dissolved
n sterile 0.9% saline solution. The LH solution was administered
ntraperitoneally (IP) at a volume of 2 ml/kg body weight; the ﬁnal
ose was 500 mg/kg. The CPA solution was microinjected at doses
f 0.016 nmol, 0.052 nmol and 0.16 nmol in a volume of 0.1 l. The
oses used were based on previous studies (Kumar et al., 2007;arch Bulletin 89 (2012) 1– 7
Privou et al., 1998; Seraﬁm et al., 2010) and on pilot work in our
laboratory.
2.3. Surgery and microinjection
Mice were bilaterally implanted with a 7-mm stainless-
steel guide cannula (25-gauge; Insight Equipamentos Cientíﬁcos
Ltda.) under general anesthesia with ketamine hydrochloride
(100 mg/kg, IP) and xylazine (10 mg/kg, IP). Stereotaxic coordinates
(Paxinos and Franklin, 2001) for the target site in the amygdala
were measured in relation to the skull surface: antero-posterior
(AP) = −0.8 mm,  lateral (L) = ±2.7 mm  and ventral (V) = −2.0 mm.
The guide cannula was ﬁxed to the skull using dental acrylic and
jeweler’s screws. During implantation, the guide cannula remained
1 mm above the target site. A dummy  cannula (33-gauge stain-
less steel wire; Fishtex Industry and Commerce of Plastics Ltda.)
was inserted into each guide cannula immediately after surgery
to reduce the incidence of occlusion. Post-operative analgesia was
provided for two days by adding acetaminophen (200 mg/ml) to the
drinking water in a ratio of 0.2 ml  acetaminophen to 250 ml  water
(i.e., a ﬁnal concentration of 0.16 mg/ml) (Messier et al., 1999).
Three days after surgical recovery, solutions were injected into
the amygdala using microinjection units (33-gauge stainless steel
cannula; Insight Equipamentos Cientíﬁcos Ltda.), which extended
1.0 mm beyond the tips of the guide cannulae. Each microin-
jection unit was attached to a 5-l  Hamilton microsyringe via
polyethylene tubing (PE-10), and administration was controlled by
an infusion pump (BI 2000; Insight Equipamentos Cientíﬁcos Ltda.)
programmed to deliver a volume of 0.1 l (volume injected) over
a period of 60 s. The microinjection procedure consisted of gently
restraining the animal, removing the dummy  cannula, inserting the
injection needle, infusing the solution, and keeping the injection
unit in situ for 60 s. Successful infusion was conﬁrmed by monitor-
ing the movement of a small air bubble in the PE-10 tubing.
2.4. Apparatus
The apparatus used for EPM testing was  similar to those devel-
oped by Lister (1987),  with a ﬂoor and walls constructed from
acrylic. The maze was  elevated to a height of 38.5 cm from the ﬂoor
and consisted of two open (30 cm × 6 cm × 0.6 cm)  arms opposite
to two enclosed (30 cm × 6 cm × 15.5 cm)  arms, extending from a
common central platform (6 cm × 6 cm). All testing was conducted
under moderate illumination (77 lux; measured on the central plat-
form of the EPM) during the light phase of the diurnal cycle.
2.5. Experimental procedure
Three days after surgery, the animals were transported to the
experimental room and left undisturbed for at least 1 h before
testing to facilitate adaptation. Trial 1 (T1) and Trial 2 (T2) were per-
formed on two  consecutive days. In T1, mice received an IP injection
of LH. Two hours later, they received an intra-amygdala microinjec-
tion of SAL or CPA. Both drugs were administered before each trial.
In T2 (24 h later), the mice were again submitted to the pharmaco-
logical treatments under the same experimental conditions. Each
test session began by placing the subject on the central platform
of the maze, facing an open arm. The subject was allowed 5 min
of free exploration. Between animals, the maze was thoroughly
cleaned with 20% alcohol and dry cloths. All sessions were video
recorded using a camera positioned above the maze and linked
to a computer in an adjacent room. Injection procedure was  done
in the amygdaloid complex as described by Baptista et al. (2009)
and Barbalho et al. (2009).  Mice received an IP injection of LH,  fol-
lowed by an intra-amygdala infusion of SAL or CPA (0.016, 0.052,
or 0.16 nmol/0.1 l) 2 h later (Huang et al., 2003). In each trial, the
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Fig. 1. Schematic representation of amygdala microinfusion sites in mice. Sections
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OAE and OAT (p > 0.05) in T1 (Table 1), indicating that LH or CPA hadre  between −1.06 and −1.46 mm from the bregma in the atlas of Paxinos and
ranklin (2001).  There are fewer sites than total mice because of overlaps.
rugs were administered prior to the test, and 5 min  after the CPA
nfusion, each mouse was submitted to EPM testing. For each CPA
ose administered, the animals were randomly assigned to four
roups based on drug treatment: SAL–SAL (IP injection and intra-
mygdala infusion of SAL), LH–SAL (IP injection of LH and infusion of
AL), SAL–CPA (IP injection of SAL and infusion of CPA) and LH–CPA
IP injection of LH and infusion of CPA).
.6. Behavioral analysis
Videotapes were scored by a highly trained observer using an
thological analysis software package X-Plo-Rat developed at the
aboratory of Exploratory Behavior, USP, Ribeirao Preto (Becerra-
arcía et al., 2005). Behavioral parameters were deﬁned according
o previous studies (Lister, 1987; Rodgers and Johnson, 1995) and
ncluded the following: frequencies of open and enclosed arm
ntries (OAE and EAE) (arm entry = all four paws into an arm), total
ime spent in open arms (OAT), total time spent in enclosed arms
EAT), and total time spent in the central area (CT). These data were
sed to calculate the percentages of OAE [%OAE; (OAE/TE) × 100]
nd OAT [%OAT; (OAT/300) × 100].
.7. Histology
At the end of the experiments, each animal received a 0.1 l
nfusion of 1% methylene blue according to the previously described
icroinjection procedure. The animals received an anesthetic over-
ose, their brains were removed and the injection sites were
icroscopically (Olympus B202) veriﬁed according to the atlas
f Paxinos and Franklin (2001).  Data from animals with injection
ites outside the amygdala were excluded from analysis. Histo-
ogical analysis conﬁrmed that 117 mice had accurate cannula
lacement in the amygdala (Fig. 1) and that the sample sizes of the
ifferent dosage cohorts were as follows: [CPA 0.016 nmol/0.1 l:
AL–SAL (n = 11), LH–SAL (n = 11), SAL–CPA (n = 10), LH–CPA (n = 8);
PA 0.052 nmol/0.1 l: SAL–SAL (n = 11), LH–SAL (n = 11), SAL–CPA
n = 9), LH–CPA (n = 8); CPA 0.16 nmol/0.1 l: SAL–SAL (n = 10),
H–SAL (n = 11), SAL–CPA (n = 9), LH–CPA (n = 8)].
As shown in Fig. 1, microinjection tips were positioned in the
mygdala and the methylene blue was within the amygdaloid com-
lex. Therefore, the present results can be interpreted as chemical
timulation of the amygdala.arch Bulletin 89 (2012) 1– 7 3
2.8. Statistics
Initially, all results were submitted to Levene’s test for homo-
geneity of variance. When appropriate, the data were square-root
transformed and then analyzed using two-way repeated measures
ANOVA (factor 1: treatment; factor 2: trial). Signiﬁcant F tests were
followed by post hoc Fisher’s LSD tests (protected t-tests). In all
cases, p values lower than 0.05 were required for signiﬁcance.
2.9. Ethics
All procedures were approved by the Ethics Committee on
Animal Experimentation of the Federal University of São Carlos
(#028/2007) and were compliant with the recommendations of the
Brazilian Society of Neuroscience and Behavior (SBNeC), which are
based on the US National Institutes of Health Guide for the Care and
Use of Laboratory Animals.
3. Results
3.1. Effects of IP injection of LH (500 mg/kg) and intra-amygdala
infusion of SAL or CPA (0.016 nmol/0.1 l) in mice exposed and
re-exposed to the EPM
Fig. 2(A) and (B) shows the treatment effects of IP LH injec-
tion (500 mg/kg) and intra-amygdala infusion of SAL or CPA
(0.016 nmol/0.1 l) on EPM behavioral measures. Two-way ANOVA
revealed no signiﬁcant treatment effects for %OAE [F(3,36) = 2.44,
p > 0.05] and %OAT [F(3,36) = 1.30, p > 0.05] or OAE and OAT (p > 0.05).
Post hoc test did not show signiﬁcant differences between SAL–SAL
and SAL–CPA or LH–SAL groups in T1 (Table 1) for these mea-
sures, indicating that the drugs did not induce changes in anxiety
level. Furthermore, ANOVA followed by Fisher’s LSD test showed
no signiﬁcant difference between groups in T1 for EAT, CT, and EAE
(p > 0.05 for all) during T1 (Table 1).
For T2, the ANOVA conﬁrmed a statistically signiﬁcant effect
of trial on %OAE [F(1,36) = 12.17, p < 0.05] and %OAT [F(1,36) = 34.38,
p < 0.05] and a statistically signiﬁcant treatment × trial interaction
for OAE [F(1,36) = 5.31, p < 0.05] and %OAT [F(1,36) = 7.81, p < 0.05].
Fisher’s LSD test showed decreased open arm exploration (%OAE
and %OAT) for the SAL–SAL and SAL–CPA groups (Fig. 2A and B).
Post hoc tests also indicated a signiﬁcant decrease in OAE and
OAT (p < 0.05) for the SAL–SAL and SAL–CPA groups from T1 to T2,
while the LH–SAL group only exhibited decreased OAE across trials
(Table 1). Importantly, %OAE and %OAT did not decrease (p > 0.05)
for the LH groups (LH–SAL or LH–CPA) in T2 (Fig. 2A and B). Further-
more, as indicated by ANOVA followed by post hoc comparisons,
the T2 EAT increased [F(1,36) = 20.09, p < 0.05] for the SAL–SAL and
LH–SAL groups, but EAE did not differ signiﬁcantly between trials
for any experimental group (p > 0.05). Fisher’s LSD test also indi-
cated that CT decreased [F(1,36) = 12.14, p < 0.05] for the SAL–SAL
and LH–SAL groups (Table 1).
3.2. Effects of IP injection of LH (500 mg/kg) and intra-amygdala
infusion of SAL or CPA (0.052 nmol/0.1 l) in mice exposed and
re-exposed to the EPM.
Fig. 3(A) and (B) show the treatment effects of IP LH injec-
tion (500 mg/kg) and intra-amygdala infusion of SAL or CPA
(0.052 nmol/0.1 l) on EPM behavioral measures. The ANOVA
revealed no signiﬁcant treatment effects on anxiety as represented
by %OAE [F(3,35) = 0.27, p > 0.05] and %OAT [F(3,35) = 2.38, p > 0.05] orno effect on anxiety. Additionally, ANOVA followed by Fisher’s LSD
test indicated no statistically signiﬁcant difference between groups
in T1 for any other measures (EAT, CT and EAE; p > 0.05) (Table 1).
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Table 1
Effects of IP LH injection (500 mg/kg) and intra-amygdala infusion of CPA (0.016, 0.052, or 0.16 nmol/0.1 l) prior to Trial 1 (T1) and prior to Trial 2 (T2) on behavioral measures
in  mice re-exposed to EPM testing.
Behaviors SAL–SAL LH–SAL SAL–CPA LH–CPA
T1 T2 T1 T2 T1 T2 T1 T2
CPA 0.016 nmol/0.1 l
EAE 4.4 ± 0.8 3.6 ± 0.8 4.8 ± 0.5 3.0 ± 0.7 3.9 ± 0.9 3.3 ± 0.7 4.8 ± 0.3 6.7 ± 1.8
OAE  3.2 ± 0.5 0.8 ± 0.1* 3.1 ± 0.4 1.7 ± 0.2* 3.2 ± 0.2 0.8 ± 0.3* 3.2 ± 0.2 3.3 ± 0.7
OAT 44.0  ± 6.6 4.5 ± 1.6* 49.5 ± 13.5 32.1 ± 7.5 33.0 ± 7.9 8.4 ± 4.2* 33.3 ± 9.2 43.0 ± 11.3
EAT  192.0 ± 17.4 268.7 ± 10.1* 175.2 ± 13.4 246.1 ± 13.4* 227.9 ± 10.5 250.3 ± 15.7 195.2 ± 19.4 216.1 ± 16.9
CT  63.9 ± 16.9 26.7 ± 9.6* 75.2 ± 13.1 21.7 ± 8.6* 39.06 ± 9.5 41.2 ± 13.5 71.4 ± 9.0 40.8 ± 7.5
CPA  0.052 nmol/0.1 l
EAE 3.6 ± 0.8 3.0 ± 0.5 4.8 ± 0.5 3.0 ± 0.7 5.5 ± 1.2 2.1 ± 0.8* 6.0 ± 1.6 2.8 ± 0.6*
OAE 2.8 ±  0.3 0.5 ± 0.2* 3.1 ± 0.4 1.7 ± 0.2* 3.3 ± 0.4 1.0 ± 0.4* 2.5 ± 0.7 1.3 ± 0.5
OAT  31.1 ± 5.8 2.9 ± 1.2* 49.5 ± 3.5 32.1 ± 7.5 33.0 ± 7.3 3.6 ± 1.4* 24.3 ± 8.3 26.5 ± 11.1
EAT  185.4 ± 24.2 274.4 ± 8.8* 175.2 ± 13.4 246.1 ± 13.4* 218.7 ± 23.1 285.6 ± 3.3 218.0 ± 3.1 236.1 ± 19.8
CT  83.4 ± 7.2 22.5 ± 8.5* 75.2 ± 3.1 21.7 ± 8.6* 47.8 ± 16.8 10.7 ± 2.3* 57.6 ± 16.5 37.3 ± 11.5
CPA  0.16 nmol/0.1 l
EAE 2.8 ± 0.5 2.6 ± 0.5 4.8 ± 0.5 3.0 ± 0.7 3.7 ± 0.6 3.4 ± 0.8 4.7 ± 0.7 3.0 ± 0.2
OAE  4.1 ± 0.8 1.2 ± 0.4* 3.1 ± 0.4 1.7 ± 0.2* 2.4 ± 0.3* 1.6 ± 0.3 2.0 ± 0.3 1.1 ± 0.1
OAT  49.1 ± 11.3 10.4 ± 5.1* 49.5 ± 3.5 32.1 ± 7.5 20.9 ± 4.1 38.2 ± 13.9 34.3 ± 11.8 30.5 ± 4.1
EAT  162.5 ± 30.3 251.3 ± 16.2 175.2 ± 13.4 246.1 ± 13.4* 199.1 ± 18.2 227.6 ± 16.9 164.8 ± 22.3 246.9 ± 4.1*
CT 88.3 ±  26.6 38.2 ± 12.3* 75.2 ± 3.1 21.7 ± 8.6* 79.8 ± 16.8 34.1 ± 14.1 100.7 ± 26.9 22.5 ± 3.3*
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fata are reported as mean ± SEM. TE = total entries; EAE = enclosed arm entries; OA
T  = time spent in the central area; *p < 0.05 for T1 compared to T2 (ANOVA, followe
As indicated in Fig. 3(A) and (B), ANOVA conﬁrmed effects for the
rial factor in %OAE [F(1,35) = 6.37, p < 0.05] and %OAT [F(1,35) = 7.48,
 < 0.05], as well as in OAE and OAT (p < 0.05), but no statistically
igniﬁcant treatment × trial interactions were observed for these
easures (p > 0.05). The post hoc comparisons indicated decreases
ig. 2. Effects of IP LH injection (500 mg/kg) and intra-amygdala (IA) infusion of SAL
r  CPA (0.016 nmol/0.1 l) on the percentage of open arm entries (%OAE) (A) and
he percentage of time spent in open arms (%OAT) (B) during Trial 1 (T1) and Trial 2
T2) in the EPM. Both drugs were administered prior to each trial. Groups: SAL–SAL
IP  and IA injection of SAL), LH–SAL (IP injection of LH and IA SAL), SAL–CPA (IP
njection of SAL and IA CPA), and LH–CPA (IP injection of LH and IA CPA). *p < 0.05
or  T1 compared to T2 (ANOVA followed by Fisher’s LSD test).en arm entries; OAT = time spent in open arms; EAE = time spent in enclosed arms;
isher LSD test).
in %OAE, %OAT, OAE and OAT (Table 1) for the SAL–SAL and SAL–CPA
groups, while the LH–SAL group only exhibited a decrease in OAE
from T1 to T2. However, open arm activity (%OAE and %OAT) did
not decrease in either LH group (LH–SAL or LH–CPA) between T1
and T2. ANOVA followed by the Fisher’s LSD test revealed a sig-
niﬁcant increase in EAT [F(1,35) = 5.66, p < 0.05] for the SAL–SAL and
LH–SAL groups and a decrease in EAE [F(1,35) = 19.99, p < 0.05] for
the SAL–CPA and LH–CPA groups in T2; only the LH–CPA group
did not exhibit a signiﬁcant decrease in CT [F(1,35) = 15.02, p < 0,05]
(Table 1).
Fig. 3. Effects of IP LH injection (500 mg/kg) and intra-amygdala (IA) infusion of SAL
or  CPA (0.052 nmol/0.1 l) on the percentage of open arm entries (%OAE) (A) and
the  percentage of time spent in open arms (%OAT) (B) during Trial 1 (T1) and Trial 2
(T2) in the EPM. Both drugs were administered prior to each trial. Groups: SAL–SAL
(IP  and IA injection of SAL), LH–SAL (IP injection of LH and IA SAL), SAL–CPA (IP
injection of SAL and IA CPA), and LH–CPA (IP injection of LH and IA CPA). *p < 0.05
for  T1 compared to T2 (ANOVA followed by Fisher’s LSD test).
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Fig. 4. Effects of IP LH injection (500 mg/kg) and intra-amygdala (IA) infusion of SAL
or  CPA (0.16 nmol/0.1 l) on the percentage of open arm entries (%OAE) (A) and the
percentage of time spent in open arms (%OAT) (B) during Trial 1 (T1) and Trial 2
(T2) in the EPM. Both drugs were administered prior to each trial. Groups: SAL–SAL
(IP  and IA injection of SAL), LH–SAL (IP injection of LH and IA SAL), SAL–CPA (IP
injection of SAL and IA CPA), and LH–CPA (IP injection of LH and IA CPA). *p < 0.05
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brain areas; one such area, the locus coeruleus, modulates the atten-
tional state and presents a tight neuromodulatory interaction withor  T1 compared to T2 (ANOVA followed by Fisher’s LSD test).
.3. Effects of IP injection of LH (500 mg/kg) and intra-amygdala
nfusion of SAL or CPA (0.16 nmol/0.1 l) in mice exposed and
e-exposed to the EPM
The treatment effects of IP injection of LH (500 mg/kg) and intra-
mygdala infusion of SAL or CPA (0.16 nmol/0.1 l) are shown in
ig. 4(A) and (B). The ANOVA revealed no statistically signiﬁcant
ffects of treatment on the anxiety measures %OAE [F(3,34) = 1.87,
 > 0.05] and %OAT [F(3,34) = 0.40, p > 0.05] or on OAE and OAT
p > 0.05) in T1 (Table 1), indicating that the drugs did not affect
nxiety. As conﬁrmed by two-way ANOVA followed by post hoc
est, there were no signiﬁcant difference between groups for EAT,
T and EAE (p > 0.05 for all) in T1 (Table 1).
ANOVA followed by Fisher’s LSD test showed that the only
tatistically signiﬁcant difference between exposures (trial effect)
bserved was  for the SAL–SAL group, in which %OAE [F(1,34) = 8.51,
 < 0.05] and %OAT [F(1,34) = 2.17, p < 0.05] decreased in T2; there
as a treatment × trial interaction in %OAE [F(1,34) = 5.39, p < 0.05].
he post hoc test indicated that the LH–SAL group exhibited
ecreased OAE during T2, but none of the other experimental
roups (SAL–CPA and LH–CPA) signiﬁcantly modiﬁed their open
rm exploration in T2 (p > 0.05). Moreover, Table 1 shows that EAT
ncreased signiﬁcantly in T2 for the SAL–SAL, LH–SAL and LH–CPA
roups [F(1,34) = 25.70, p < 0.05], while CT [F(1,34) = 20,62, p < 0.05]
ecreased for all groups except SAL–CPA. Post hoc comparisons also
howed no changes in EAE in T2 compared to T1 (p > 0.05) for any
xperimental group (Table 1).arch Bulletin 89 (2012) 1– 7 5
4. Discussion
The main results of this study demonstrate that systemic
administration of l-histidine and intra-amygdala microinjection of
chlorpheniramine (CPA) did not affect behavioral measures of anx-
iety. LH impairs emotional memory in a state dependent manner,
in EPM procedure; CPA in the amygdala does not interact with LH
effect, but induces impairment per se at the highest dose, in mice
re-exposed to the elevated plus-maze. Importantly, no signiﬁcant
changes were observed in the number of enclosed arm entries (EAE)
in T1, a parameter considered to be a valid measure of locomo-
tor activity in the elevated plus-maze (Cruz et al., 1994). Since the
amygdala is very small in mice and the drugs diffuse, these results
may  be attributed to a combined effect in the different nucleus of
the amygdaloid complex.
Our results show that LH (500 mg/kg, IP) injected prior to T1
did not affect anxiety because there was no signiﬁcant difference
in open arm activity (%OAE and %OAT) between SAL–SAL and the
LH–SAL group during T1. In contrast, Kumar et al. (2007) showed
that IP LH injection before EPM exposure induced anxiogenic-like
effects in mice. Other studies have also shown that histamine
administered into the basolateral amygdala induces anxiogenic-
like behaviors in rats exposed to the EPM (Bananej et al., 2012;
Zarrindast et al., 2011). The discrepancies between our ﬁndings
and these previously reported experiments could be related to
experimental differences among the many factors that seem to
inﬂuence aversion to the open arms, such as the time of day at
which testing occurs (Griebel et al., 1993) and the levels of illu-
mination in the testing room (García et al., 2011). However, our
results are consistent with previous studies conducted in our labo-
ratory, which have shown that IP LH (500 mg/kg) injection does not
change anxiety levels in mice re-exposed to the EPM (Gianlorenc¸ o
et al., 2011; Seraﬁm et al., 2010). Intra-amygdala infusion of CPA
(0.016, 0.052, or 0.16 nmol) also did not appear to affect anxiety
because there was  no signiﬁcant difference between the SAL–SAL
and the group that received a CPA infusion (SAL–CPA). Privou et al.
(1998) reported that unilateral injection of CPA at a dosage of 20 g
or 0.1 g into the nucleus basalis magnocellularis (NBM) provoked
anxiolytic-like effects in rats. In a recent report, systemic injection
and local injection of CPA into the medial portion of the prefrontal
cortex (mPFC) attenuated anxiety and fearful responses in mice
through the activation of serotoninergic system (5-HT) (Miyata
et al., 2011). These discrepancies concerning the role played by
H1 receptors may  be related to the different injection sites used
to evaluate anxiety-like responses.
We detected a notable decrease in open arm activity (%OAE and
%OAT) for the SAL–SAL and SAL–CPA groups at a dose of 0.016 or
0.052 nmol during T2. Our results indicate that learning occurred
for these groups in T1 and that emotional memory was evoked in T2.
However, our results showed that the LH–SAL groups that received
IP LH injection did not exhibit decreased open arm activity dur-
ing T2 relative to T1, indicating that these mice did not remember
aversive information about the open arms during T2. Our results
corroborate previous studies from our laboratory that showed that
systemic LH injection induced retrieval deﬁcits of aversive informa-
tion of open arms in a state-dependent manner (Gianlorenc¸ o et al.,
2011; Seraﬁm et al., 2010). Our data are in accordance with other
behavioral studies that have shown impairment in learning and
memory induced by Histamine (Ahmadi et al., 2010; Rubio et al.,
2001).
The anatomical organization of histaminergic neurons suggests
that this system might inﬂuence the neuronal activity of largethe amygdala (McGaugh, 2004). In addition, some amines such as
histamine have been shown to have a biphasic, non-linear dose
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ffect on memory processes, and these amines likely act on emo-
ional arousal levels (Baldi and Bucherelli, 2005). In our view,
he IP LH injection could shift the curve action of histamine and
ecreased activation in the locus coeruleous. It has been demon-
trated that noradrenergic nucleus has a direct projection to the
mygdala (McGaugh, 2004), suggesting that this pathway has an
mportant role in modulating memory storage in rats (McIntyre
t al., 2011) and during retrieval of emotional memories in humans
Sterpenich et al., 2006). Histamine effects would consequently
ecrease adrenergic activity in the amygdala, and thus, attention
evel and performance would also decrease.
Considering the evidence of the involvement of H1 receptors in
motional learning and memory processes (Alvarez and Banzan,
008; Zarrindast et al., 2002) and the well-described projections
rom the histaminergic nucleus to the amygdala, we hypothesized
hat the blockade of H1 receptors in this structure would prevent
H effects on emotional memory retrieval. However, our results
ot only suggest that LH impairs emotional memory in EPM proce-
ure; they further demonstrated that CPA in the amygdala does not
nteract with LH effect, but induces emotional memory impairment
er se at the highest dose. It has been proposed that histaminergic
ystem inﬂuences cognitive processes by modulating the choliner-
ic activation (Blandina et al., 2004). Histamine excites cholinergic
eurons of the NBM through H1 receptor activation (Khateb et al.,
995). Further, rats that received intrahippocampal administration
f the histamine H1 receptor antagonist pyrilamine increased the
umber of errors in the working memory task and these effects
ere signiﬁcantly reduced by infusion of the histamine H1 recep-
or agonist 2-pyridylethylamine (Nakazato et al., 2000). In other
tudy, emotional reactivity to spatial novelty is altered in H1R
nockout mice, possibly due to changes in amygdala acetylcholine
evels (Zlomuzica et al., 2008). We  suggest that the highest dose
f H1-antagonist chlorpheniramine could lead to decreased acetyl-
holinergic activity from the NBM to the amygdala, which would
mpair the emotional memory expression. Our results suggest that
istamine exerts its procognitive effect on memory via an interac-
ion with cholinergic system, but this hypothesis has not yet been
ested.
Therefore, the present results may  be due to the effect of
istamine on one of the well-organized amygdalar projections,
ndicating that emotional behavior expression in rodents is under
he tonic modulatory control of this neurotransmitter.
. Conclusion
In conclusion, the results indicate that that l-histidine and H1
eceptors present in the amygdala are involved in emotional mem-
ry but do not mediate anxiety-related behaviors in mice submitted
o EPM testing.
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